Topic: microsatellite instability-high cancer
The results are out, and they’re practice-changing: Keytruda can double the time to progression in patients with certain types of colorectal cancer.
Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.
Bristol-Myers Squibb's got a new indication for Opdivo that’ll help it vie with Merck’s Keytruda in colorectal cancer.
Talk about going on a roll. Merck’s Keytruda nabbed a first-ever FDA approval to treat a very specific type of tumor anywhere in the body.